-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The establishment of the Hong Kong office will enhance Oculis' global influence and help its development strategy in the Chinese market.
Hong Kong, October 8, 2021/PRNewswire/ - Oculis SA ("Oculis"), a biopharmaceutical company focused on clinical development and research, is pleased to announce the establishment of its Hong Kong office to enhance the company's strategic location in China and Asia Future development and business capabilities
At the same time, Oculis announced the appointment of Dr.
Dr.
Dr.
Dr.
Before joining Novartis, Dr.
Dr.
About Oculis
Oculis is a biopharmaceutical company headquartered in Lausanne, Switzerland, with operations in Europe, the United States and China, focusing on the development of new ophthalmic drug formulations to improve and restore the vision of patients around the world